Fujirebio strengthens its diagnostic tools for Parkinson’s disease with an acquisition
Fujirebio Holdings’ portfolio of biomarkers and diagnostic tools for Parkinson’s disease now includes tailored antibodies against the protein alpha-synuclein with the company’s acquisition of ADx NeuroSciences.
The $40 million acquisition is expected to close in July, pending satisfaction of customary closing conditions.
Fujirebio, a subsidiary of HU Group Holdings, is an R&D company focused on the development of high quality laboratories (also called in vitro) diagnostics for neurodegenerative and other diseases.
“By welcoming ADx NeuroSciences to the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and neurodegenerative contract development and manufacturing (CDMO) offerings to our partners globally. world,” said Goki Ishikawa, Chairman and CEO of Fujirebio Holdings. , said in a press release from the company. A CDMO company has both drug development programs and manufacturing departments.
A hallmark feature of Parkinson’s disease is the buildup of toxic clumps of misfolded alpha-synuclein protein, known as Lewy bodies, in dopamine-producing nerve cells – those responsible for releasing dopamine, a neurotransmitter. These protein aggregates are toxic to cells and contribute to synaptic degeneration, loss of communication between nerve cells, and nerve cell death.
It should be noted that neurotransmitters are chemicals produced in response to nerve signals that allow these cells to communicate.
As part of Fujirebio, ADx NeuroSciences will continue to develop its portfolio of biomarkers and antibodies as diagnostic and prognostic tools for Parkinson’s disease and other neurodegenerative diseases, including Alzheimer’s disease.
The company’s current portfolio includes two antibodies against alpha-synuclein, with others in development, as well as biomarkers for synaptic degeneration.
“Fujirebio is committed to investing in the development of diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We are excited to work with the ADx NeuroSciences team to expand the global market for neurodegeneration biomarker testing,” said Ishikawa.
According to the press release, ADx, which specializes in the development of tests for pharmaceuticals and companies performing in vitro diagnostic tests, will continue to serve its current partners and customers.
Fujirebio reports that its acquisition of ADx will add know-how, expertise and resources to the Fujirebio Neuro Center of Excellence, a global center of expertise in the diagnosis of neurodegenerative diseases.